Therapy
Female CEOs
Health

Halozyme Therapeutics

$16.54
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.20 (-1.19%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell HALO and other stocks, options, ETFs, and crypto commission-free!

About

Halozyme Therapeutics, Inc. Common Stock, also called Halozyme Therapeutics, is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. Read More It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Employees
281
Headquarters
San Diego, California
Founded
1998
Market Cap
2.42B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
814.72K
High Today
$16.90
Low Today
$16.49
Open Price
$16.76
Volume
430.28K
52 Week High
$21.41
52 Week Low
$13.24

Collections

Therapy
Female CEOs
Health
Pharmaceutical
Biopharmaceutical
Biotechnology
Medical
Technology

News

Simply Wall StMar 14

If You Had Bought Halozyme Therapeutics (NASDAQ:HALO) Stock Three Years Ago, You Could Pocket A 100% Gain Today

One simple way to benefit from the stock market is to buy an index fund. But if you choose individual stocks with prowess, you can make superior returns. Just take a look at Halozyme Therapeutics, Inc. (NASDAQ:HALO), which is up 100%, over three years, soundly beating the market return of 39% (not including dividends). View our latest analysis for Halozyme Therapeutics Halozyme Therapeutics isn’t a profitable company, so it is unlikely we’ll see a strong correlation between its share price and its earning...

115
Seeking AlphaMar 11

Avid Bioservices, Inc. (CDMO) CEO Roger Lias on Q3 2019 Results - Earnings Call Transcript

Avid Bioservices, Inc. (NASDAQ:CDMO) Q3 2019 Results Earnings Conference Call March 11, 2019 4:30 PM ET Company Participants Tim Brons - Investor Relations Roger Lias - President and Chief Executive Officer Daniel Hart - Chief Financial Officer Conference Call Participants Joseph Pantginis - H.C. Wainwright Paul Knight - Janney Montgomery Steven Schwartz - First Analyst Operator Good day, ladies and gentlemen, and welcome to the Avid Bioservices’ Third Quarter 2019 Financial Results Conference Cal...

76
Yahoo FinanceMar 4

Halozyme To Participate In Upcoming Investor Conferences

SAN DIEGO, March 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in two upcoming investor conferences. The 39 th Annual Cowen Healthcare Conference on Monday, March 11 at 4:50 p.m. ET / 1:50 p.m. PT in Boston, MA. Dr. Helen Torley , president and chief executive officer, will present an overview of the company. Annual Cowen Healthcare Conference on at / in Dr. , president and chief executive officer...

42

Earnings

-$0.24
$0.12
$0.49
$0.85
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 9, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.